File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/01.tp.0000789500.50801.c7
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Role of novel immunosuppressive CD10+ antigen-presenting neutrophils in promoting HCC tumorgenesis
Title | Role of novel immunosuppressive CD10+ antigen-presenting neutrophils in promoting HCC tumorgenesis |
---|---|
Authors | |
Issue Date | 2021 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com |
Citation | 2021 Virtual International Congress of ILTS, ELITA and LICAGE, 5-8 May 2021. In Transplantation, 2021, v. 105 n. 8S, p. 31 How to Cite? |
Abstract | Introduction: High circulating neutrophil-to-lymphocyte ratio is a biomarker of poor clinical outcome in HCC and various cancers. Neutrophils have long been considered as key components in the innate immune system. Recent evidence has shown GM-CSF is highly expressed in the peritumoral area of HCC and can induce expression of MHC-II (HLA-DR) on polymorphonuclear neutrophils. However, limited findings are available on both the immunological roles of the cytokine and its activated neutrophil sub-population in HCC. Based on our preliminary findings, we hypothesized the novel antigen-presenting phenotype of neutrophils (defined as CD66b+ HLA-DR+) have a pivotal role in HCC tumorigenesis.
Methods: The expression of CD66b and HLA-DR in 45 HCC clinical specimens were quantified using quantitative PCR. Immunohistochemistry and flow cytometry were used to confirm the presence of CD66b+ HLA-DR+ neutrophil subpopulation.
Results: Our qPCR data showed that CD66b, HLA-DR, CD10 mRNA level were elevated in peritumoural areas of HCC patients, and significantly correlated with each other (p< 0.001) (Fig.1). Consistent findings were confirmed in immunohistochemistry and flow cytometry(Fig 2). Clinical analysis also demonstrated that CD66b+ HLA-DR+ CD10+ neutrophils significantly correlated with tumour size, recurrence, staging, venous infiltration (Fig. 3) and negatively correlated with disease-free survival and overall survival of HCC patients (p< 0.05).
Conclusion: The results collectively indicated the novel tumour promoting roles of CD66b+ HLA-DR+ CD10+ neutrophils in HCC patients. Targeting such population may represent a potential therapeutic strategy. |
Description | Concurrent Oral Abstract Session, Track 4: Immunosuppression and Tolerance Induction - no. O-059 |
Persistent Identifier | http://hdl.handle.net/10722/308112 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.371 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | CHENG, YHF | - |
dc.contributor.author | Yeung, WHO | - |
dc.contributor.author | Pang, L | - |
dc.contributor.author | Man, K | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2021-11-12T13:42:41Z | - |
dc.date.available | 2021-11-12T13:42:41Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | 2021 Virtual International Congress of ILTS, ELITA and LICAGE, 5-8 May 2021. In Transplantation, 2021, v. 105 n. 8S, p. 31 | - |
dc.identifier.issn | 0041-1337 | - |
dc.identifier.uri | http://hdl.handle.net/10722/308112 | - |
dc.description | Concurrent Oral Abstract Session, Track 4: Immunosuppression and Tolerance Induction - no. O-059 | - |
dc.description.abstract | Introduction: High circulating neutrophil-to-lymphocyte ratio is a biomarker of poor clinical outcome in HCC and various cancers. Neutrophils have long been considered as key components in the innate immune system. Recent evidence has shown GM-CSF is highly expressed in the peritumoral area of HCC and can induce expression of MHC-II (HLA-DR) on polymorphonuclear neutrophils. However, limited findings are available on both the immunological roles of the cytokine and its activated neutrophil sub-population in HCC. Based on our preliminary findings, we hypothesized the novel antigen-presenting phenotype of neutrophils (defined as CD66b+ HLA-DR+) have a pivotal role in HCC tumorigenesis. Methods: The expression of CD66b and HLA-DR in 45 HCC clinical specimens were quantified using quantitative PCR. Immunohistochemistry and flow cytometry were used to confirm the presence of CD66b+ HLA-DR+ neutrophil subpopulation. Results: Our qPCR data showed that CD66b, HLA-DR, CD10 mRNA level were elevated in peritumoural areas of HCC patients, and significantly correlated with each other (p< 0.001) (Fig.1). Consistent findings were confirmed in immunohistochemistry and flow cytometry(Fig 2). Clinical analysis also demonstrated that CD66b+ HLA-DR+ CD10+ neutrophils significantly correlated with tumour size, recurrence, staging, venous infiltration (Fig. 3) and negatively correlated with disease-free survival and overall survival of HCC patients (p< 0.05). Conclusion: The results collectively indicated the novel tumour promoting roles of CD66b+ HLA-DR+ CD10+ neutrophils in HCC patients. Targeting such population may represent a potential therapeutic strategy. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com | - |
dc.relation.ispartof | Transplantation | - |
dc.relation.ispartof | 2021 Virtual International Congress of ILTS, ELITA & LICAGE | - |
dc.title | Role of novel immunosuppressive CD10+ antigen-presenting neutrophils in promoting HCC tumorgenesis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Yeung, WHO: why21@hku.hk | - |
dc.identifier.email | Pang, L: leepang@connect.hku.hk | - |
dc.identifier.email | Man, K: kwanman@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.authority | Man, K=rp00417 | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.description.nature | abstract | - |
dc.identifier.hkuros | 330014 | - |
dc.identifier.volume | 105 | - |
dc.identifier.issue | 8S | - |
dc.identifier.spage | 31 | - |
dc.identifier.epage | 31 | - |
dc.publisher.place | United States | - |
dc.identifier.partofdoi | 10.1097/01.tp.0000789500.50801.c7 | - |